SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (2336)6/23/1999 2:30:00 AM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
So, you are saying that at this last hour, CIST decided to buy back shares just to help the shareholders increase the value of a stock in a company that nobody seems to be interested in buying or merging with? Well, we agree to disagree.

Why is August 31, 1999 the deadline to submit a proposal to Genome about CIST?




To: John Metcalf who wrote (2336)6/26/1999 4:01:00 AM
From: Walter Morton  Respond to of 2742
 
Look at this:

ZMTX is a development stage biotechnology company engaged in the discovery and development of unique products for the diagnosis and treatment of viruses.

Sales: $.5 million;
Profit: Negative 1600%;
Cash: $10 million

biz.yahoo.com

Isn't it appalling that ZMTX sells for $2 while CIST is at $.37.

So, they have fewer shares outstanding, but they have a bigger loss.




HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News